INTERCEPT Blood System for Platelets

About Cerus

Cerus is a public company focused exclusively on blood safety, aiming to become the preeminent global blood products company. Its flagship INTERCEPT Blood System for platelets and plasma is the only pathogen reduction system with both FDA approval and a CE mark for these components. With a commercial footprint and a late-stage pipeline for red blood cells, Cerus is positioned to address critical safety gaps in the global blood transfusion market.

Therapeutic Areas